⭐ High Impact

How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.

von Mühlen Carlos Alberto, Garcia-De La Torre Ignacio, Infantino Maria, Damoiseaux Jan, Andrade Luis E C, Carballo Orlando Gabriel, Conrad Karsten, Francescantonio Paulo Luiz Carvalho, Fritzler Marvin J, Herold Manfred, Klotz Werner, de Melo Cruvinel Wilson, Mimori Tsuneyo, Satoh Minoru, Musset Lucile, Chan Edward K L

📰 Immunologic research 📅 2021 📊 75 citations

Abstract

Results of the anti-nuclear antibodies-indirect immunofluorescence assay (anti-cell antibodies test) on HEp-2 cell substrates should be communicated to clinicians in a standardized way, adding value to laboratory findings and helping with critical clinical decisions. This paper proposes a test report based on the practices informed by 118 laboratories in 68 countries, with recommendations from the International Consensus on ANA Patterns (ICAP) group. Major focus is placed on the report format containing endpoint titers, immunofluorescence patterns together with anti-cell (AC) nomenclature, remarks on follow-up or reflex testing, and possible other autoantibody associations. ISO 15,189 directives were integrated into the test report. Special situations addressed include serum screening dilutions and endpoint titers, relevance of immunofluorescence patterns with special attention to cytoplasmic patterns, mixed and compound patterns, and how to report different titers corresponding to multiple patterns or autoantibodies in the same sample. This paper suggests a subtitle for the HEp-2-IIFA, namely anti-cell antibodies test, which could gradually substitute the original outdated ANA nomenclature. This ICAP pro forma report represents a further step in harmonizing the way relevant clinical information could be provided by laboratories.

🔬 Techniques

✨ Fluorophores

🧪 Sample Preparation

🔬 Cell Lines

🏭 Microscope Brands

Evident (Olympus)

🏛️ Research Organizations (ROR)

Affiliated research institutions:

📊 Figures

Fig. 1

Immunofluorescent antinuclear antibodies in patients with rheumatic diseases. a Nuclear speckled pattern. b Centromere. c Mitotic spindle apparatus (NuMA). d Antimitochondria and nuclear dots. e GW bo...

Fig. 2

Prevalence of autoantibodies associated with scleroderma and polymyositis/dermatomyositis (PM/DM). Commercially available tests ( shaded ) and other disease-related autoantibodies are indicated

Fig. 3

Characterization of various autoantibodies by immunoprecipitation. a Protein analysis by immunoprecipitation. 35 S-methionine-labeled K562 cell lysate was immunoprecipitated by sera from Mexican patie...

Figure images are served from the NIH/NLM PubMed Central Open Access Subset or Europe PMC; copyright remains with the publishers and authors.

🏛️ Imaging Facility

🏛️ Hospital Moinhos de Vento

💬 Discussion

0 comments

No comments yet. Be the first to start a discussion!

Leave a Comment

MicroHub Assistant